Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Its Hypertension Franchise in Crisis, Novartis Restructures

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.

Advertisement

Related Content

Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE
Actavis Hypertension Combo Prompts Discussion Of “Me-Too” Drug Standards
FDA Keeps Calcitonin Products On The Market But Narrows Osteoporosis Claim
FDA Panel To Consider Calcitonin Drugs’ Need For Fracture Data In Light Of Potential Cancer Risk
Salmon-Derived Osteoporosis Drugs Face Upstream Struggle Against Cancer Concerns
Where’s Generic Diovan? Ranbaxy’s Valsartan ANDA In Limbo As Novartis’ Patent Expires
Where’s Generic Diovan? Ranbaxy’s Valsartan ANDA In Limbo As Novartis’ Patent Expires
Novartis To Increase Marketing Support As New Products Drive Growth In The Second Quarter
Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame
Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel